222 related articles for article (PubMed ID: 28415728)
1. Lipid degradation promotes prostate cancer cell survival.
Itkonen HM; Brown M; Urbanucci A; Tredwell G; Ho Lau C; Barfeld S; Hart C; Guldvik IJ; Takhar M; Heemers HV; Erho N; Bloch K; Davicioni E; Derua R; Waelkens E; Mohler JL; Clarke N; Swinnen JV; Keun HC; Rekvig OP; Mills IG
Oncotarget; 2017 Jun; 8(24):38264-38275. PubMed ID: 28415728
[TBL] [Abstract][Full Text] [Related]
2. HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study.
Dundr P; Bártů M; Hojný J; Michálková R; Hájková N; Stružinská I; Krkavcová E; Hadravský L; Kleissnerová L; Kopejsková J; Hiep BQ; Němejcová K; Jakša R; Čapoun O; Řezáč J; Jirsová K; Franková V
Sci Rep; 2020 Sep; 10(1):14365. PubMed ID: 32873863
[TBL] [Abstract][Full Text] [Related]
3. Lipid Uptake Is an Androgen-Enhanced Lipid Supply Pathway Associated with Prostate Cancer Disease Progression and Bone Metastasis.
Tousignant KD; Rockstroh A; Taherian Fard A; Lehman ML; Wang C; McPherson SJ; Philp LK; Bartonicek N; Dinger ME; Nelson CC; Sadowski MC
Mol Cancer Res; 2019 May; 17(5):1166-1179. PubMed ID: 30808729
[No Abstract] [Full Text] [Related]
4. ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
Centenera MM; Scott JS; Machiels J; Nassar ZD; Miller DC; Zinonos I; Dehairs J; Burvenich IJG; Zadra G; Chetta PM; Bango C; Evergren E; Ryan NK; Gillis JL; Mah CY; Tieu T; Hanson AR; Carelli R; Bloch K; Panagopoulos V; Waelkens E; Derua R; Williams ED; Evdokiou A; Cifuentes-Rius A; Voelcker NH; Mills IG; Tilley WD; Scott AM; Loda M; Selth LA; Swinnen JV; Butler LM
Cancer Res; 2021 Apr; 81(7):1704-1718. PubMed ID: 33547161
[TBL] [Abstract][Full Text] [Related]
5. SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer.
Audet-Walsh É; Vernier M; Yee T; Laflamme C; Li S; Chen Y; Giguère V
Mol Cancer Res; 2018 Sep; 16(9):1396-1405. PubMed ID: 29784665
[TBL] [Abstract][Full Text] [Related]
6. Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis.
Gu Y; Xue M; Wang Q; Hong X; Wang X; Zhou F; Sun J; Wang G; Peng Y
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948018
[No Abstract] [Full Text] [Related]
7. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of Eci3, a murine kidney-specific Δ3,Δ2-enoyl-CoA isomerase.
van Weeghel M; Ofman R; Argmann CA; Ruiter JP; Claessen N; Oussoren SV; Wanders RJ; Aten J; Houten SM
FASEB J; 2014 Mar; 28(3):1365-74. PubMed ID: 24344334
[TBL] [Abstract][Full Text] [Related]
9. MiR-133a-5p inhibits androgen receptor (AR)-induced proliferation in prostate cancer cells via targeting FUsed in Sarcoma (FUS) and AR.
Zheng L; Kang Y; Zhang L; Zou W
Cancer Biol Ther; 2020; 21(1):34-42. PubMed ID: 31736422
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells.
Huang WC; Zhau HE; Chung LW
J Biol Chem; 2010 Mar; 285(11):7947-56. PubMed ID: 20071336
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells.
Song IS; Jeong YJ; Kim J; Seo KH; Baek NI; Kim Y; Kim CS; Jang SW
Cell Mol Life Sci; 2020 Nov; 77(22):4663-4673. PubMed ID: 31894360
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of androgen receptor and β-catenin activity in prostate cancer.
Lee E; Madar A; David G; Garabedian MJ; Dasgupta R; Logan SK
Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15710-5. PubMed ID: 24019458
[TBL] [Abstract][Full Text] [Related]
13. Positive regulation of prostate cancer cell growth by lipid droplet forming and processing enzymes DGAT1 and ABHD5.
Mitra R; Le TT; Gorjala P; Goodman OB
BMC Cancer; 2017 Sep; 17(1):631. PubMed ID: 28877685
[TBL] [Abstract][Full Text] [Related]
14. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.
Olsen JR; Azeem W; Hellem MR; Marvyin K; Hua Y; Qu Y; Li L; Lin B; Ke X; Øyan AM; Kalland K
BMC Cancer; 2016 Jul; 16():377. PubMed ID: 27378372
[TBL] [Abstract][Full Text] [Related]
15. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer.
Ding M; Jiang CY; Zhang Y; Zhao J; Han BM; Xia SJ
J Exp Clin Cancer Res; 2020 Feb; 39(1):28. PubMed ID: 32019578
[TBL] [Abstract][Full Text] [Related]
16. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
17. Long-Chain Acyl-CoA Synthetase 4-Mediated Fatty Acid Metabolism Sustains Androgen Receptor Pathway-Independent Prostate Cancer.
Ma Y; Zhang X; Alsaidan OA; Yang X; Sulejmani E; Zha J; Beharry Z; Huang H; Bartlett M; Lewis Z; Cai H
Mol Cancer Res; 2021 Jan; 19(1):124-135. PubMed ID: 33077484
[TBL] [Abstract][Full Text] [Related]
18. Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.
Asim M; Massie CE; Orafidiya F; Pértega-Gomes N; Warren AY; Esmaeili M; Selth LA; Zecchini HI; Luko K; Qureshi A; Baridi A; Menon S; Madhu B; Escriu C; Lyons S; Vowler SL; Zecchini VR; Shaw G; Hessenkemper W; Russell R; Mohammed H; Stefanos N; Lynch AG; Grigorenko E; D'Santos C; Taylor C; Lamb A; Sriranjan R; Yang J; Stark R; Dehm SM; Rennie PS; Carroll JS; Griffiths JR; Tavaré S; Mills IG; McEwan IJ; Baniahmad A; Tilley WD; Neal DE
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26657335
[TBL] [Abstract][Full Text] [Related]
19. HNF1B expression regulates ECI2 gene expression, potentially serving a role in prostate cancer progression.
Dan C; Zhang H; Zeng W; Huang L; Gong X; Li H; Yang E; Wang L; Yao Q
Oncol Lett; 2019 Jan; 17(1):1094-1100. PubMed ID: 30655870
[TBL] [Abstract][Full Text] [Related]
20. Stearoyl CoA desaturase (SCD) facilitates proliferation of prostate cancer cells through enhancement of androgen receptor transactivation.
Kim SJ; Choi H; Park SS; Chang C; Kim E
Mol Cells; 2011 Apr; 31(4):371-7. PubMed ID: 21331774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
